RGLD:NASDAQRoyal Gold, Inc. Analysis
Data as of 2026-06-21 - not real-time
$214.82
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Royal Gold (RGLD) is trading at $214.82, well below its DCF fair value of $251.79, implying roughly 52% upside. The forward P/E of about 16x contrasts with a trailing P/E near 26x, indicating earnings acceleration. Operating margins are robust at ~64% and gross margin at 87%, reflecting the high‑margin royalty business. Dividend yield sits at 0.88% with a modest payout ratio of 22%, suggesting sustainability. Technicals show a neutral trend, but the MACD line has crossed above its signal, producing a bullish histogram, while RSI at 46 points to room for upside. Volume is increasing and price holds above the identified support of $195.76, giving a cushion for a rebound.
Recent news notes a 5.4% share decline since the last earnings release and a bearish analyst note linked to a stake reduction, adding short‑term pressure. However, the company’s diversified royalty portfolio across more than a dozen countries mitigates geographic concentration risk. Volatility is elevated at 41% 30‑day and beta above 1, underscoring market sensitivity but also potential reward. The upcoming virtual roadshow signals management’s willingness to engage investors. Overall, the combination of strong cash‑flow generation, undervalued pricing, and a defensive royalty model supports a positive outlook.
Recent news notes a 5.4% share decline since the last earnings release and a bearish analyst note linked to a stake reduction, adding short‑term pressure. However, the company’s diversified royalty portfolio across more than a dozen countries mitigates geographic concentration risk. Volatility is elevated at 41% 30‑day and beta above 1, underscoring market sensitivity but also potential reward. The upcoming virtual roadshow signals management’s willingness to engage investors. Overall, the combination of strong cash‑flow generation, undervalued pricing, and a defensive royalty model supports a positive outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent 5.4% price decline post‑earnings
- Bullish MACD crossover with neutral trend
- Support level at $195.76 providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation vs DCF fair value (~52% upside)
- Strong royalty cash‑flow and high margins
- Low dividend payout ratio indicating sustainability
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Defensive royalty business model with diversified geography
- Attractive valuation relative to forward earnings
- Sustainable dividend and low payout ratio supporting income appeal
Key Metrics & Analysis
Financial Health
Revenue Growth143.00%
Profit Margin48.91%
P/E Ratio26.0
ROE11.98%
ROA8.10%
Debt/Equity7.98
P/B Ratio2.5
Op. Cash Flow$862.0M
Free Cash Flow$-409444384
Technical Analysis
TrendNeutral
RSI46.0
Support$195.76
Resistance$228.15
MA 20$215.23
MA 50$233.18
MA 200$228.32
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46
Valuation
Fair Value$251.79
Target Price$326.67
Upside/Downside52.07%
GradeUndervalued
TypeValue
Dividend Yield0.88%
Risk Assessment
Beta1.29
Volatility41.48%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.